Announcements
- uniQure Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Investigational Gene Therapy AMT-130 in Huntington’s Disease
- uniQure Announces First Quarter 2024 Financial Results and Highlights Recent Company Progress
- uniQure Announces 2023 Financial Results and Highlights Recent Company Progress
- uniQure Announces Update on Phase I/II Clinical Trials of AMT-130 Gene Therapy for the Treatment of Huntington’s Disease
- uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- uniQure Announces FDA Clearance of Investigational New Drug Application for AMT-191 Gene Therapy for Fabry Disease
- uniQure Announces Third Quarter 2023 Financial Results and Highlights Recent Company Progress
- uniQure Announces Major Presence at the European Society of Gene and Cell Therapy (ESGCT) Annual Meeting
- uniQure Announces Strategic Reorganization to Reduce Operating Expenses and Support Advancement of Multiple Clinical-Stage Programs
- uniQure Announces FDA Clearance of Investigational New Drug Application for AMT-260 Gene Therapy for Refractory Mesial Temporal Lobe Epilepsy
More ▼
Key statistics
On Friday, Uniqure NV (0EE0:LSE) closed at 5.25, 22.26% above the 52 week low of 4.29 set on Apr 30, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | -- |
---|---|
High | -- |
Low | -- |
Bid | -- |
Offer | -- |
Previous close | 5.25 |
Average volume | 2.51k |
---|---|
Shares outstanding | 48.55m |
Free float | 46.47m |
P/E (TTM) | -- |
Market cap | 263.14m USD |
EPS (TTM) | -6.20 USD |
Data delayed at least 20 minutes, as of Jun 07 2024 17:48 BST.
More ▼